Novartis has acknowledged that its neuromuscular candidate delpacibart etedesiran (del-desiran) failed a pivotal Phase III ...

Tyra Biosciences (TYRA) downgraded to Hold ahead of phase 2 SURF302 data; review FGFR3-targeting SNAP platform, cash runway, ...

Explore the preclinical research catching our eye in September 2026, from siRNA and in vivo CRISPR to targeted protein ...

Opus Genetics (IRD) receives a Buy rating following >30% stock surge on positive Phase 1/2 data for OPGx-BEST1 in ...

Neil McCormick picks his favourite songs from pop’s most explosively abundant decade in our next instalment of Music of the ...

Follow live coverage as Republicans attend the second day of the first-ever midterm primary convention on September 10 in ...

Across three visual specialties, machines are finding abnormalities faster and remembering change over time, shifting doctors ...

The $6.5 million project is a collaboration among Gannon, AHN Saint Vincent and First Ascent Biomedical, a Miami-based ...

How visual-based assessment assists researchers to judge cellular identity and avoid experimental bias HUSTON, TX, ...

Most business leaders in 2026 understand, at least in principle, that AI represents a significant opportunity. Fewer have a ...

Arm CEO sees AI accelerating cancer diagnosis, research and treatment, and actually curing types of the disease in the future ...

Spread the love“`html The conversation around artificial intelligence in healthcare has reached a fever pitch, moving far ...